Abstracts tagged "Animal models and systemic sclerosis"

Abstract Number: 112 • 2018 ACR/ARHP Annual Meeting
Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells
Emma C. Derrett-Smith^1,2, Shiwen Xu¹, Rachel K. Hoyles³, Olivier Lacombe⁴, Pierre Broqua⁴, Jean-Louis Junien⁴, Irena Konstantinova⁵ and Christopher P. Denton^6,7, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Inventiva, DAIX, France, ⁵Inventiva, Daix, France, ⁶UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: The TβRIIΔk-fib transgenic (TG) mouse model of scleroderma carries a fibroblast-specific TGFβ receptor II mutation resulting in balanced up-regulation of TGFβ signalling and replicates…
Abstract Number: 1510 • 2012 ACR/ARHP Annual Meeting
Critical Role of the Adhesion Receptor Dnax Accessory Molecule-1 (DNAM-1) in the Development of Inflammation-Driven Dermal Fibrosis in Mouse Model of Systemic Sclerosis
Jerome Avouac¹, Muriel Elhai², Michal Tomcik³, Manuel Friese⁴, Marco Colonna⁵, Günter Bernhardt⁶, Andre Kahan⁷, Gilles Chiocchia⁸, Joerg HW Distler⁹ and Yannick Allanore¹⁰, ¹Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ²Paris Descartes University, INSERM U1016, Institut Cochin, Sorbonne Paris Cité, Paris, France, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic, ⁴Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, ⁵Washington University, Department of Immunology, St. Louis, MO, ⁶Institute of Immunology, Hannover Medical School, Hannover, Germany, ⁷Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France, ⁸Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104), Paris, France, ⁹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France
Background/Purpose: DNAX accessory molecule 1 (DNAM-1) is an adhesion factor involved in the adhesion and co-stimulation of T cells. DNAM-1 has been recently identified as…
Abstract Number: 1514 • 2012 ACR/ARHP Annual Meeting
Differences in the Activation Levels and Expression Patterns of the Molecular Targets of Tyrosine Kinase Inhibitors May Account for the Heterogeneous Treatment Responses
Britta Maurer¹, Alfiya Akhmetshina², Renate E. Gay³, Beat A. Michel³, Steffen Gay⁴, Joerg H. W. Distler² and Oliver Distler³, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland
Background/Purpose: In SSc, treatment responses to tyrosine kinase inhibitors (TKI) are less distinct compared to animal models. Therefore, we assessed whether the heterogeneous therapeutic effects…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].